新型载药微球栓塞治疗肝脏肿瘤的初步经验.docVIP

新型载药微球栓塞治疗肝脏肿瘤的初步经验 (浙江大学医学院附属第一医院肝胆胰介入中心 浙江 杭州310003) 目的观察新型载药栓塞微球(Hepasphere)治疗肝脏肿瘤的安全性 及其近期临床疗效。方法12例肝脏肿瘤患者在肝动脉化疗栓塞术中使用 Hepasphere微球栓塞，对患者临床资料、影像随访资料、介入治疗的并发症和 预后等情况进行总结和分析。采用mRESCIST标准，术后每月随访一次。12例肝 脏肿瘤患者中，男性7例，女性5例，年龄43?69岁，中位年龄51岁。12例 患者共行22次TACEo其中原发性肝癌5例，转移性肝癌7例(原发肿瘤为结 直肠癌3例，胆囊癌1例，神经内分泌癌1例，胰腺癌1例，胃癌1例)。结果 12例患者随访7?12月，中位随访时间为9月，根据mRESCIST标准，3月疾病 缓解率为50%,疾病控制率为83.3%, 6月疾病缓解率为33.3%,疾病控制率为 75%o所有患者均未出现胆汁漏并发感染、肝脓肿、腹腔出血、肿瘤破裂出血及 消化道出血等严重并发症。少数患者术后当天腹痛较重，需盐酸哌替噪止痛，其 他患者腹痛较轻。结论应用新型栓塞微球(Hepasphere)治疗肝脏肿瘤的近期 临床疗效及安全性均较好，远期效果仍需大量病例进一步观察。 【关键词】TACE；肝脏肿瘤；Hepasphere微球；载药微球 R73 A 2095-1752 (2016) 02-0156-02 Embolization with Hepasphere drug eluting microsphere for treatment of Liver cancer Zhou Guanhui, Sun Junhui, Zhang Yuelin, Nie Chunhui, Zhou Tanyang, Zhu Tongyin, Wu Jian, Wang Weilin, Zheng Shusen. The Center of Hepatobiliary and Pancreatic Intervention, First Affiliated Hospital, College of Medicin巳 Zhejiang University, Hangzhou 310003, China [Abstract] Objective To evaluate the therapeutic results and safety of treatment for liver cancer with a new kind of microsphere. Methods 12 patients with liver cancer underwent TACE with Hepasphere microsphere. The clinical data, imaging follow-up data, complicatio ns of interve ntional treatme nt and prog nosis were summarized and analyzed. Local response was evaluated with modified response evaluation criteria in solid tumors (mRECIST) . There were 7 male, 5 female and the median age was 51 years? A total of 22 IACE procedures were performed in 12 patients. There were 5 patients with HCC and 7 patents with liver metastases (the primary tumor sites in eluded: colorectal ca, n euroe ndocri ne ca, gallbladder ca, pan creatic ca, gastric ca) ? Results The follow up period ranged from 7 months to 12 months (mid 9 mon ths). The 3-month objective response rate was 50%, and disease control rate was 83.3%. The 6-month objective response rate was 33.3%, and disease control rate was 75%. In all the patients, no severe complications, such